Search Results

June 9, 2012

Canagliflozin Provided Substantial and Sustained Glycemic Improvements as Monotherapy and in Add-On Combinations in Adults with Type 2 Diabetes in Five Phase 3 Studies

Canagliflozin Provides Greater Reduction of A1C Levels in Adults with Type 2 Diabetes in 52-Week Head-to-Head Studies Compared to Sitagliptin and Glimepiride

Innovative Medicine

June 6, 2012

New STELARA® Five-Year Data Show Consistent Efficacy and Safety Profile in Treatment of Moderate to Severe Plaque Psoriasis

Findings from the Only Psoriasis Clinical Development Program for a Biologic Following Patients Continuously for Five Years Provide Insights on STELARA Long-Term Response and Safety Profile

Innovative Medicine

June 5, 2012

New Phase 3 Data Show STELARA® Significantly Reduced Signs And Symptoms Of Active Psoriatic Arthritis

Treatment with STELARA Also Resulted in Significant Improvements in Physical Function, Enthesitis and Dactylitis, and Plaque Psoriasis

Innovative Medicine

June 5, 2012

New Phase 3 Data Show SIMPONI® Intravenous Formulation Significantly Improved Rheumatoid Arthritis Signs And Symptoms In Patients With Active Disease

Study Findings Include Results of SIMPONI Intravenous Formulation on Rheumatoid Arthritis Associated Fatigue

Innovative Medicine

June 2, 2012

ZYTIGA® Plus Prednisone Show Improvements in Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer

Phase 3 Results Show Significant Improvement in Radiographic Progression-Free Survival and a Trend for Increased Overall Survival in Patients Receiving ZYTIGA Plus Prednisone

Innovative Medicine

May 31, 2012

Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes

Innovative Medicine

May 29, 2012

FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet

Innovative Medicine

May 23, 2012

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

Innovative Medicine

May 23, 2012

Janssen Healthcare Innovation Announces Discharge Decision Support System (D2S2) Winner of the Janssen Connected Care Challenge

$100,000 award to advance commercialization of D2S2 transition care solution designed to deliver better patient care and reduce hospital readmissions

Innovative Medicine

May 21, 2012

New Phase 3 Study Results Show Anti-TNF SIMPONI® Induced Clinical Response in Adults with Moderately To Severely Active Ulcerative Colitis

First Presentation of Phase 3 Data Shows Significant Improvements in Clinical Remission, Mucosal Healing and Quality of Life Measures after SIMPONI Induction Treatment

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine